Incyte says pancreatic cancer drug combo shows lasting tumor responses

Incyte reported that its targeted drug, used with chemotherapy, induced lasting tumor responses in specific pancreatic cancer patients. The biotech stated these results support its prior decision to advance the treatment into a late-stage clinical trial.

Revolution Medicines received approval earlier this year for Rasonque, a drug targeting mutations in the RAS gene group. It showed that medicines attacking these mutations can prolong survival in the aggressive disease. Now, Incyte, Revolution Medicines, Verastem, and China’s Hengrui are developing next-generation drugs to selectively target specific mutations within the RAS family. They seek better outcomes through more precise targeting.